Study to Assess the Efficacy and Safety of Orismilast in Psoriasis

Inclusion Criteria:

Capable of giving signed informed consent.
Male and female patients ≥18 years of age
Body weight of >40 kg
Diagnosis of chronic, stable plaque-type psoriasis. If the patient is diagnosed with psoriasis arthritis, the arthritis should be stable.
Moderate-to-severe plaque-type psoriasis as defined by Psoriasis Activity and Severity Index (PASI) ≥12, body surface area (BSA) ≥10%, and Investigator Global Assessment (IGA) ≥3.
Candidate for systemic antipsoriatic treatment or phototherapy.

Exclusion Criteria:

Therapy-resistant psoriasis
Unstable psoriasis or psoriatic arthritis with acute deterioration within 4 weeks of the Screening visit.
History of allergy or hypersensitivity to any component of the study treatment.
Active infection (eg, bacteria, viral, fungal) requiring treatment with systemic antibiotics within 4 weeks of the Screening visit.
Malignancy or history of malignancy except for treated (ie, cured) basal cell skin carcinomas.